Compare C3.ai Inc (AI) vs Viatris Inc (VTRS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
C3.ai Inc vs Viatris Inc — how do they compare? C3.ai Inc trades at $8.85 (market cap $1.39B), while Viatris Inc trades at $16.6 (market cap $19.75B). The key difference: Viatris Inc is far larger — about 14.2× C3.ai Inc's market cap, and Viatris Inc pays a 2.83% dividend while C3.ai Inc pays none. Which is the better fit depends on your goals.
| AI | VTRS | |
|---|---|---|
Market Cap | $1.39B | $19.75B |
Sector | Technology | Health |
52-Week High | $29.16 | $17.39 |
52-Week Low | $7.76 | $8.74 |
Enterprise Value | $818.29M | $31.96B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
C3.ai trades at $8.93, down 1.43% with bearish technical signals. The company shows revenue growth to $389M in 2025 but continues significant losses with -$289M net income. Analyst sentiment is mixed with 21% buy ratings and consensus target of $10.20. Recent developments include board member Jim Hagemann Snabe's appointment as European Commission Special Envoy for Industrial AI.
While revenue growth presents opportunity, persistent losses and negative cash flow pose substantial risk. The stock faces headwinds from unprofitability despite beating some earnings estimates. Upside potential exists if the company can accelerate path to profitability amid growing enterprise AI adoption.
Viatris (VTRS) trades at $16.96, up 1.56% on the day and near its 52-week high of $17.53. The stock shows a bullish technical trend with consistent earnings beats in recent quarters. However, fundamentals reveal challenges, including a net loss of $3.51 billion in 2025 and negative profit margins, though revenue remains stable around $14.3 billion. Positive developments include a strong pipeline, with recent FDA acceptance of a new drug application for fast-acting meloxicam and positive Phase 3 results for VR-205.
The outlook is mixed; analyst consensus is a 'Hold' with a $20 price target, suggesting modest upside. Key opportunities lie in pipeline catalysts and debt reduction, but risks include persistent profitability issues, high debt levels, and competitive pressures. The stock's valuation metrics like P/S of 1.35 may appeal to value investors, but earnings sustainability is a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
